| Title | Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer |
|-------|----------------------------------------------------------------------------------------------------------------------------------|
| Author(s) | Eto, Kazunori; Kawakami, Hiroshi; Kuwatani, Masaki; Kudo, Taiki; Abe, Yoko; Kawahata, Shuhei; Takasawa, Akira; Fukuoka, Midori; Matsuno, Yoshihiro; Asaka, Masahiro; Sakamoto, Naoya |
| Citation | BRITISH JOURNAL OF CANCER, 108(7), 1488-1494 |
| Issue Date | 2013-04-16 |
| Doc URL | http://hdl.handle.net/2115/53423 |
| Type | article (author version) |

**File Information**

bjc.2013.108.pdf

Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP
Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer

A running title: Predictive genes of gemcitabine effect in pancreatic cancer

Kazunori Eto 1, Hiroshi Kawakami 1, Masaki Kuwatani 1, Taiki Kudo 1, Yoko Abe 1, Shuhei Kawahata 1, Akira Takasawa 2, Midori Fukuoka 2, Yoshihiro Matsuno 2, Masahiro Asaka 3, and Naoya Sakamoto 1

1 Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
2 Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan
3 Department of Cancer Preventive Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Author contributions: Eto K and Kawakami H contributed equally to this work.

Address correspondence to: Hiroshi Kawakami, MD, PhD
Department of Gastroenterology, Hokkaido University Graduate School of Medicine,
Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan.

Tel: +81 11 716 1161 (Ext 5920); Fax: +81 11 706 7867

E-mail: hiropon@med.hokudai.ac.jp (H. Kawakami)

**A conflict of interest statement**

Financial support for this study was provided by the *Pancreas Research Foundation Japan* (H.K.). The authors report no conflicts of interest.

**Author contributions**

Kawakami H managed the patients, performed the endoscopic examination; Eto K and Kawakami H designed the research and provided discussion; Eto K, Takasawa A, and Fukuoka M performed tissue preparation and analyzed the data; Eto K, Kawakami H analyzed the data; Kuwatani M, Kudo T, Kawahata S, and Abe Y analyzed the data and provided clinical advice; Matsuno Y diagnosed the case of pathology; Eto K and Kawakami H collected the data and wrote the paper; Asaka M and Sakamoto N supervised the research; all authors approved the final manuscript for publication.
ABSTRACT

OBJECTIVES: Pancreatic ductal carcinoma (PDC) is one of the most lethal human carcinomas. Expression patterns of some genes may predict gemcitabine (GEM) treatment efficacy. We examined predictive indicators of survival in GEM-treated patients by quantifying the expression of several genes in pre-treatment endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) samples from patients with PDC.

METHODS: The expressions of hENT1, dCK, RRM1, RRM2 and Notch3 in EUS-FNA tissue samples from 71 patients with unresectable PDC were quantified using real-time reverse transcription-polymerase chain reactions and examined for correlations with GEM sensitivity. RESULTS: The log-rank test detected no significant differences in overall survival between GEM-treated patients with low and high mRNA levels of all genes examined. However, low Notch3 mRNA expression was significantly associated with longer overall survival in a multivariate analysis for survival ($P = 0.0094$). High hENT1 expression level was significantly associated with a longer time to progression ($P = 0.039$). Interaction tests for GEM administration and hENT1 or Notch3 mRNA expression were statistically significant ($P = 0.0054$ and $P = 0.0047$, respectively). CONCLUSIONS: hENT1 and Notch3 mRNA expression in EUS-FNA specimens are key predictive biomarkers of GEM effect and GEM sensitivity in patients.
with unresectable PDC.

**Keywords:** EUS-FNA; hENT1; Notch3; unresectable pancreatic cancer.
Abbreviations

PDC, Pancreatic ductal carcinoma

GEM, gemcitabine

EUS-FNA, endoscopic ultrasound-guided fine-needle aspiration

US, abdominal ultrasound

CT, computed tomography

AC, adjuvant chemotherapy

OS, overall survival

hENT1, human equilibrative nucleoside transporter 1

dCK, deoxycitidine kinase

RRM1, ribonucleoside reductase 1

RRM2, ribonucleoside reductase 2

mRNA, messenger ribonucleic acid

qRT-PCR, quantitative real-time reverse transcription-polymerase chain reaction

TTP, time to progression

HRs, hazard ratios

CIs, confidence intervals

UICC, Unio Internationalis Contra Cancrum
EMT, epithelial–mesenchymal transition

TTP, time to progression
**Introduction**

Pancreatic ductal carcinoma (PDC) is one of the most lethal human cancers. PDCs are usually unresectable (80–90%) at the time of diagnosis, despite recent progress in imaging modalities. Gemcitabine (GEM) has been the standard first-line chemotherapy agent for unresectable PDC (Burris et al., 1997). Only 10–20% of patients with PDC are candidates for curative resection (Matsuno et al., 2004). Even if curative resection is performed, the postoperative 5-year survival rate is only 15–25% because of a high rate of recurrence (Wagner et al., 2004). Recently, two randomised clinical phase III trials of adjuvant chemotherapy (AC) for PDC showed significant increases in overall survival (OS) and disease-free survival (DFS) (Neoptolemos et al., 2004; Oettle et al., 2007).

Therefore, adjuvant chemotherapy is important for patients with PDC. If GEM could be appropriately and selectively administered to patients with GEM sensitivity based on the expression of genes in the tumour, maximal chemotherapy efficacy could be achieved without subjecting GEM-resistant patients to unnecessary side effects.

Recent investigations using cell lines or surgical specimens have revealed that the expression of several genes may be predictors of GEM efficacy in GEM-treatment patients. Such GEM efficacy predictor genes include human equilibrative nucleoside transporter 1 (hENT1), the major mediator of GEM uptake in human cells (Farrell et al.,
2009); GEM-metabolism-related enzymes such as deoxycytidine kinase (dCK) (Maréchal et al., 2010)]; GEM resistance-related enzymes such as ribonucleoside reductase 1 (RRM1) (Nakahira et al., 2007), ribonucleoside reductase 2 (RRM2) (Itoi et al., 2007) and Notch3 (Yao et al., 2010), which is related to GEM-induced caspase-mediated apoptosis. Ashida et al. (2009) and Itoi et al. (2007) demonstrated that levels of expression of these genes correlated with GEM sensitivity in patients with unresectable PDC. The aim of this study was to determine a predictive indicator of survival and GEM sensitivity in GEM-treated patients with unresectable PDC by examining gene expression in pre-treatment tissue biopsy samples obtained by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA).

**Methods**

**Patients**

The study included 185 consecutive patients in whom pancreatic masses had been identified by abdominal ultrasound (US) or computed tomography (CT) and who underwent EUS-FNA at Hokkaido Hospital between October 2007 and September 2010. Subjects were excluded if they had an extrapancreatic mass, tumour histology other than ductal adenocarcinoma or preoperative evidence of resectable PDC. Finally, the
analysed population comprised a consecutive series of 71 patients (Figure 1).

**EUS-FNA procedure**

EUS was performed using an oblique forward-viewing electronic linear scanning video echoendoscope equipped with an elevator and a 3.7-mm-diameter working channel (GF-UCT240-AL5; Olympus Co., Ltd., Tokyo, Japan). The echoendoscope was connected to a processor with a colour Doppler function (SSD-5500; Aloka Co., Ltd., Tokyo, Japan). EUS-FNA was performed before treatment, as described previously (Itoi et al., 2005). Briefly, the lesions were identified using B-mode imaging. The absence of vessels in the target area was confirmed with the colour Doppler mode. After determination of an adequate angle to the tumour, an aspiration needle was introduced into the lesion. While suction was applied through the catheter connected to the needle using a 20-mL syringe, the needle was moved back and forth 10–20 times within the tumour. Negative pressure was released before the needle was removed from the lesion. To obtain sufficient tissue for RNA extraction and pathological diagnosis, several biopsy specimens were collected from each tumour by EUS-FNA using 22-gauge aspiration needles (ECHOTIP ULTRA; Cook Japan, Tokyo, Japan). A cytologist immediately examined the specimens for cancer cells using part of
the obtained tissue. We performed an additional one to two punctures after conventional
diagnostic puncture to obtain adequate tissue for RNA extraction.

**mRNA extraction**

Tissue and blood collected from the obtained specimens were examined for
confirmation of carcinoma cells by an on-site cytologist. The remaining tissue was
instantly transferred to a 1.5-mL micro test tube (Eppendorf, Saxony, Germany) and
frozen at -80°C until use. The test tube that was used to inactivate the RNase was rinsed
with 0.1 N NaOH/1 mM EDTA and diethylpyrocarbonate (DEPC) and was stored at
room temperature. Tissue samples were crushed in a mortar and placed on ice for RNA
detection. Total RNA was isolated using the TRIzol Reagent method. Total RNA
concentration was determined by spectrophotometer (NanoDrop2000c; Thermo, Tokyo,
Japan), and 1 μg total RNA was reverse transcribed using a Transcript First Strand
cDNA Synthesis kit (Roche Diagnostics K.K., Tokyo, Japan). Quantification of the
target cDNA and an internal reference gene (β2-microglobulin, β2M) was conducted by
quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR).

**qRT-PCR**
We designed specific primers using Primer-BLAST (NCBI, http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The following primers were used for real-time PCR: dCK, forward primer, 5´-TCAAGCCACTCCAGAGACATGCTT-3´; reverse primer, 5´-TGTCCTATGCAGGAGCCAGCTTTTCA-3´; hENT1, forward primer, 5´-GGCCCAAGAAAGTGAAGCCA-3´; reverse primer, 5´-ACCACTCAGGATCACCCCTG -3´; RRM1, forward primer, 5´-TCAAGGTGGGAAACAAGCGTC-3´; reverse primer, 5´-CGCTGCTCTTCCTTTTCTGT-3´; RRM2, forward primer, 5´-ACGGAGCCGAAAACCTAAAGCAGCT-3´; reverse primer, 5´-AGAGTCCACCTCCTCGGCG-3´; Notch3, forward primer, 5´-TCCAGATTTCATCCGAAACCAGCT-3´; reverse primer, 5´-GGGTCTCCTCCTTGATCTACCTGCAT-3´. qRT-PCR was performed using a Rotor-Gene Q (QIAGEN, Hilden, Germany) for 40 cycles at 95°C for 5 s and 60°C for 10 s using a SYBR Green PCR Master Mix (QIAGEN), according to the manufacturer’s instructions. Quantification was performed using the relative standard curve method. The standard curve was created automatically by Rotor-Gene Q by plotting the threshold cycle (Ct) against each input amount (containing 107, 106, 105 104, 103, 102, and 101 copies) of standard plasmid DNA. The standard plasmid DNA was created by
direct cloning using a TA cloning vector and the PCR product generated using the specific primers described above and checked by sequencing. The correlation coefficient determined by linear regression (r) for each standard curve was greater than 0.990. The relative amount of each unknown sample was calculated by linear regression analysis from the respective standard curve. A relative target-gene expression value for β2M was used as an internal reference gene.

Target mRNA

Expressions of dCK, hENT1, RRM1, RRM2, and Notch3 were examined as genetic predictive markers associated with GEM transport and metabolism.

Statistical analyses

The primary endpoint was survival in GEM-treated patients with unresectable PDC according to the expression levels of the examined genes. The cut-off for analysis of survival was April 30, 2011. The secondary endpoint was time to progression (TTP) in the patients. Survival and TTP curves were estimated using the Kaplan-Meier technique. Differences between the survival curves and those between TTP curves were assessed using the log-rank test. The Cox proportional hazard regression model was used for
multivariate analyses of survival and for estimating hazard ratios (HRs) with 95% confidence intervals (CIs). The $\chi^2$ test was used to compare proportions. Statistical analyses were performed after dichotomising subgroups as follows: hENT1 low versus high, dCK low versus high, RRM1 low versus high, RRM2 low versus high, and Notch3 low versus high. The thresholds were determined by the median of the mRNA expression in each of the 71 patients.

A value of $P < 0.05$ was considered to indicate statistical significance. All statistical analyses were performed using JMP ver. 9.0 software (SAS Institute, Gary, NC, USA).

This study was carried out in accordance with the Institutional Review Board guidelines (Hokkaido University Hospital, clinical research approval number 010-0152), and written informed consent was obtained from all patients.

Results

Patient characteristics

The clinical characteristics of the 56 patients who received GEM-based chemotherapy (GEM population) and the 15 who did not (non-GEM population) are shown in Table 1. There was no significant difference between the groups for all clinical characteristics.
**mRNA expression**

Total RNA was successfully extracted from all specimens from the patients. The mean RNA concentration was 124 ± 85 ng/μL (mean ± SD) (range 13.2–478.8). The mean dCK, hENT1, RRM1, RRM2, and Notch3 mRNA levels relative to the β2M internal reference gene were 63 ± 79 (range 0–546), 590 ± 620 (5–3,178), 576 ± 3,973 (0.3–41,508), 757 ± 2,195 (5–13,286), 242 ± 629 (0–4,490), respectively.

**Association between overall survival and mRNA expression levels in patients treated with GEM**

Patients with low Notch3 mRNA levels tended to have a better prognosis than those with high Notch3 mRNA level (low vs. high = 23.6 vs. 19.3 months, *P* = 0.068).

However, there were no tendencies and no significant differences in overall survival between patients with low and high mRNA levels of hENT1 (low vs. high = 23.6 vs. 20 months, *P* = 0.302), dCK (low vs. high = 23.6 vs. 20 months, *P* = 0.930), RRM1 (low vs. high = 27.7 vs. 19.3 months, *P* = 0.215), and RRM2 (low vs. high = 20 vs. 27.7 months, *P* = 0.520) (Figure 2).
**Association between time to progression and mRNA expression levels in the GEM-treated population**

The patients with high hENT1 (low vs. high = 15 vs. 21 months, $P = 0.051$) or low Notch3 (low vs. high = 31 vs. 21 months, $P = 0.051$) mRNA levels had longer TTP than the patients with low hENT1 or high Noch3 mRNA levels. In contrast, there were no differences in TTP between patients with low and high mRNA levels of dCK ($P = 0.162$), RRM1 ($P = 0.200$) and RRM2 ($P = 0.225$) (Figure 3).

**Factors associated with overall survival of all patients with unresectable pancreatic cancer**

Multivariate analysis for survival of all patients with unresectable PDC based on the Cox proportional hazard model was performed on all parameters described in Table 2. Survival was significantly associated with Notch3 expression levels (HRs, high vs. low = 1.00 vs. 0.0255, $P = 0.0094$) (Table 2). Although a significant difference was not observed, a tendency for the prognosis to be long was seen in patients with high hENT1 expression levels (HRs, high vs. low = 1.00 vs. 0.0333, $P = 0.074$). Interaction tests for GEM administration and hENT1 or Notch3 mRNA expression levels were statistically significant ($P = 0.0054$ and 0.0047, respectively). Furthermore, we examined predictors
of TTP in all patients. Multivariate analysis for TTP based on the Cox proportional hazard model was also performed on all parameters described in Table 3. A high hENT1 expression level was significantly associated with a long TTP (high vs. low = 1.00 vs. 29.9; \( P = 0.039 \)) (Table 3).

**Discussion**

In this prospective study, we demonstrated that the expression levels of the hENT1 and Notch3 genes are promising predictive markers for GEM-responsiveness in patients with unresectable PDC. The possibility that Notch3 was a prognostic predictive factor was considered on the basis of the results shown in Table 2. Furthermore, the possibility that hENT1 was a predictive of GEM responsiveness was suggested by the results shown in Table 3. Interaction tests involving these two genes supported the possibility that they are predictive of GEM responsiveness.

hENT1 is a major GEM transporter that is overexpressed in pancreatic cancer cells (Garcia-Manteiga \textit{et al.}, 2003). Expression of hENT1 mRNA in resected specimens from patients with pancreatic cancer is associated with long overall survival, disease-free survival, and time to disease progression (Giovannetti \textit{et al.}, 2006; Farrell \textit{et al.}, 2009; Raphael \textit{et al.}, 2012). Our results of multivariable analysis and interaction
testing are compatible with the findings of previous reports. However, due to the
limitation represented by the small non-GEM-treated population, we could not compare
Kaplan-Meier curves of the non-GEM population vs. those of the GEM-treated
population.

Notch3 plays important roles in the control of cell extracellular interactions,
such as spreading, migration, motility, and survival in pancreatic cancer cells (Dang et
al., 2006). The Notch signalling pathway is involved in the acquisition of the
epithelial–mesenchymal transition (EMT) phenotype related to invasion of pancreatic
cancer cells, and down-regulation of Notch signalling is associated with decreased
invasive behaviour of pancreatic cancer cells, followed by partial reversal of the EMT
phenotype (Wang et al., 2009). In previous reports regarding resected PDC specimens,
Notch3 was frequently overexpressed in PDC lesions compared with normal pancreatic
ductal tissue (Doucas et al., 2008). Meanwhile, nuclear Notch3 expression was
clinically correlated with a lower overall survival time of PDC patients (Doucas et al.,
2008) and also other carcinomas such as ovarian carcinoma (Park et al., 2010).
Additionally, it was reported that suppression of Notch3 expression decreased the
average half maximal inhibitory concentration (IC50) of GEM in pancreatic cell lines
(Yao et al., 2010). Thus, there may be at least two pathways for the GEM effect:
suppression of Notch3 expression by GEM, and amplification of the GEM effect through the suppression of Notch3.

To-date, there has been no report of the relationship between the effectiveness of GEM and Notch3 mRNA expression in the clinical course of PDC. For the first time, our results using pre-treatment EUS-FNA specimens suggest that Notch3 is a promising informative biomarker for predicting the effectiveness of GEM and GEM sensitivity in patients with unresectable PDC. Using Kaplan-Meier analysis of OS and TTP and multivariate analysis for OS, our expression data and clinical results might be used to address the results of patients with low Notch3 mRNA levels compared to patients with high levels. However, further study in more patients is needed to confirm this correlation.

EUS-FNA is widely used as a cytological and histological sample collection tool for pancreatic cancer (Khalid et al., 2006; Takahashi et al., 2005), and there have been some reports of oncogene analysis in pancreatic cancer using EUS-FNA samples (Ashida et al., 2009; Khalid et al., 2006; Tada et al., 2002; Buchholz et al., 2005). The reliability of tests based on tissue or cell extracts is often dependent on the relative abundance of the target cell population. Moreover, sampling errors or a large number of “contaminating cells” can lead to false-negative results (Fujita et al., 2008). This is
likely why Fujita et al. were unable to detect significant differences in mRNA levels among whole-cell pellet samples; however, they could distinguish higher and lower expression of each gene among neoplastic cell samples by microdissection (Fujita et al., 2010). In the present study, we could distinguish higher and lower expression of genes by selection of white tissue on site, although we used total RNA isolated from EUS-FNA tissue samples without microdissection. It may be important to trim white tissue for high-quality RNA analysis, although there is no evidence to support this. In addition, some reports suggest that flow cytometry and cytogenetic analysis or improvement of diagnostic accuracy using specimens of EUS-FNA could be achieved using a thick 19-G needle instead of a 21- or 25-G needle puncture (Yasuda et al., 2011). Therefore, further development of methods for sample collection and processing are required to improve wide genetic analysis of EUS-FNA specimens.

If GEM sensitivity could be predicted using specimens collected by EUS-FNA at the same time as pathological diagnosis, the appropriate anticancer agents such as oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) could be selected (Conroy et al., 2011). Furthermore, based on the results of RNA analyses of EUS-FNA specimens, the appropriate preoperative neoadjuvant chemotherapy could be administered.
There are several limitations to our study. One is that the sample size and observation period were not sufficient. Another limitation is that this was a retrospective and single centre study. To address these issues, a large scale, multicentre prospective study is needed.

In conclusion, based on genetic analysis of EUS-FNA tissue samples, our data suggest that hENT1 and Notch3 mRNA expression levels are promising novel and informative biomarkers for predicting and monitoring Gem sensitivity in patients with unresectable PDC.

**Acknowledgments**

The authors thank Mr. K. Marukawa (Department of Surgical Pathology, Hokkaido University Hospital) for skillful cytologic examination and analysis. The authors also thank Dr. Y. Hatanaka (Department of Surgical Pathology, Hokkaido University Hospital) for skillful examination and analysis. We also thank Dr. K. Ooba (Clinical Trial Center, Hokkaido University Hospital) for conducting the statistical analyses.
References

Ashida R, Nakata B, Shigekawa M, Mizuno N, Sawaki A, Hirakawa K, Arakawa T, Yamao K (2009) Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer. J Exp Clin Cancer Res 28: 83

Buchholz M, Kestler HA, Bauer A, Böck W, Rau B, Leder G, Kratzer W, Bommer M, Scarpa A, Schilling MK, Adler G, Hoheisel JD, Gress TM (2005) Specialized DNA arrays for the differentiation of pancreatic tumors. Clin Cancer Res 11(22): 8048-54

Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6): 2403-13
Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364(19):1817-25.

Dang L, Fan X, Chaudhry A, Wang M, Gaiano N, Eberhart CG (2006) Notch3 signaling initiates choroid plexus tumor formation. Oncogene 25(3): 487-91

Doucas H, Mann CD, Sutton CD, Garcea G, Neal CP, Berry DP, Manson MM (2008) Expression of nuclear Notch3 in pancreatic adenocarcinomas is associated with adverse clinical features, and correlates with the expression of STAT3 and phosphorylated Akt. J Surg Oncol 97(1): 63-8

Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR (2009) Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136(1): 187-95
Fujita H, Ohuchida K, Mizumoto K, Egami T, Miyasaka Y, Yamaguchi H, Yu J, Cui L, Onimaru M, Takahata S, Tsuneyoshi M, Tanaka M (2008) Quantitative analysis of hTERT mRNA levels in cells microdissected from cytological specimens. Cancer Sci 99(11): 2244-51

Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T, Tanaka M (2010) Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 12(10): 807-17

Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M (2003) Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. Clin Cancer Res 9(13): 5000-8

Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, Mosca F, Danesi R (2006) Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66(7): 3928-35
Itoi T, Sofuni A, Fukushima N, Itokawa F, Tsuchiya T, Kurihara T, Moriyasu F, Tsuchida A, Kasuya K (2007) Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas. J Gastroenterol 42(5): 389-94

Itoi T, Takei K, Sofuni A, Itokawa F, Tsuchiya T, Kurihara T, Nakamura K, Moriyasu F, Tsuchida A, Kasuya K (2005) Immunohistochemical analysis of p53 and MIB-1 in tissue specimens obtained from endoscopic ultrasonography-guided fine needle aspiration biopsy for the diagnosis of solid pancreatic masses. Oncol Rep 13(2): 229-34

Khalid A, Nodit L, Zahid M, Bauer K, Brody D, Finkelstein SD, McGrath KM (2006) Endoscopic ultrasound fine needle aspirate DNA analysis to differentiate malignant and benign pancreatic masses. Am J Gastroenterol 101(11): 2493-500

Marechal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, Andr T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I,
Deviere J, Emile JF, Van Laethem JL (2012) Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 143(3): 664-674.e6

Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Salmon I, Deviere J, Van Laethem JL (2010) Deoxycytidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 116(22): 5200-6

Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K (2004) Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 28(3): 219-30

Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, Yamasaki M, Marubashi S, Takemasa I, Miyamoto A, Takeda Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M (2007) Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 120(6): 1355-63
Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Böhler MW, Cancer ESOGfP (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350(12): 1200-10

Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297(3): 267-77

Park JT, Chen X, Tropè CG, Davidson B, Shih IeM, Wang TL (2010) Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol 177(3):1087-94.

Tada M, Komatsu Y, Kawabe T, Sasahira N, Isayama H, Toda N, Shiratori Y, Omata M
(2002) Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. Am J Gastroenterol 97(9): 2263-70

Takahashi K, Yamao K, Okubo K, Sawaki A, Mizuno N, Ashida R, Koshikawa T, Ueyama Y, Kasugai K, Hase S, Kakumu S (2005) Differential diagnosis of pancreatic cancer and focal pancreatitis by using EUS-guided FNA. Gastrointest Endosc 61(1): 76-9

Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Bhler MW (2004) Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91(5): 586-94

Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH (2009) Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69(6): 2400-7
Yao J, Qian C (2010) Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway. Med Oncol 27(3): 1017-22

Yasuda I, Goto N, Tsurumi H, Nakashima M, Doi S, Iwashita T, Kanemura N, Kasahara S, Adachi S, Hara T, Shimizu M, Takami T, Moriwaki H (2012) Endoscopic ultrasound-guided fine needle aspiration biopsy for diagnosis of lymphoproliferative disorders: feasibility of immunohistological, flow cytometric, and cytogenetic assessments. Am J Gastroenterol 107(3):397-404
### Table 1. Clinical characteristics of patients.

|                         | GEM population  | Non-GEM population | P value $\chi^2$ test |
|-------------------------|-----------------|--------------------|-----------------------|
| **Median age in years (range)** |                 |                    |                       |
| < 69 years              | 69 (37-88)      | 68 (49-84)         | 0.023                 |
| > 68 years              | 24 (43%)        | 8 (53%)            |                       |
|                         | 32 (57%)        | 7 (47%)            |                       |
| **Sex**                 |                 |                    |                       |
| Male                    | 26 (46.4%)      | 9 (60%)            | 0.349                 |
| Female                  | 30 (53.6%)      | 6 (40%)            |                       |
| **Location**            |                 |                    |                       |
| Ph                      | 24 (42.9%)      | 6 (40%)            | 0.842                 |
| Pb and Pt               | 32 (57.1%)      | 9 (60%)            |                       |
| **UICC TNM 7th f-Stage**|                 |                    |                       |
| Stage III               | 17 (30.4%)      | 3 (20%)            | 0.346                 |
| Stage IV                | 39 (69.6%)      | 12 (80%)           |                       |
| **Performance status**  |                 |                    |                       |
| 0                       | 49 (87.5%)      | 11 (73.3%)         | 0.201                 |
| 1-3                     | 7 (12.5%)       | 4 (26.7%)          |                       |
| **Comorbidities**       |                 |                    |                       |
| Some                    | 39 (69.6%)      | 11 (73.3%)         | 0.779                 |
| None                    | 17 (30.4%)      | 4 (26.7%)          |                       |
| **GEM efficacy**        |                 |                    |                       |
| CR                      | 0 (0%)          |                    |                       |
| PR                      | 1 (1.8%)        |                    |                       |
| SD                      | 34 (60.7%)      |                    |                       |
| PD                      | 21 (37.5%)      |                    |                       |
| **No. of chemotherapy cycles, median (range)** | 4 (1-31) | | |

GEM, gemcitabine; Ph, head of the pancreas; Pb, body of the pancreas; Pt, tail of the pancreas; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
| Patient stratification               | n     | HR   | 95% CI       | P value |
|-------------------------------------|-------|------|--------------|---------|
| Age (years) < 69 / ≥ 69             | 32 / 39 | 1 / 3.83 | 0.44-68.0 | 0.229  |
| Sex Female / Male                    | 36 / 35 | 1 / 0.154 | 0.011-1.12 | 0.06   |
| Location Ph / Pb & Pt                | 30 / 41 | 1 / 7.31  | 0.29-728   | 0.244  |
| UICC TNM 7th f-Stage III / IV        | 21 / 50 | 1 / 0.0384 | 0.000347-0.734 | 0.0275 |
| Performance status 0 / 1-3           | 65 / 11 | 1 / 0.000127 | 0-117429839 | 0.995  |
| Comorbidities Some / None            | 50 / 21 | 1 / 0.0557 | 0.0007-0.682 | 0.020  |
| GEM-treated Yes / No                 | 56 / 15 | 1 / 0.209  | 0.00204-8.75 | 0.419  |
| hENT1 High / Low                     | 33 / 38 | 1 / 29.9   | 0.730-2918  | 0.074  |
| dCK High / Low                       | 38 / 33 | 1 / 4.098  | 0.371-61.8  | 0.236  |
| RRM1 High / Low                      | 37 / 34 | 1 / 0.515  | 0.0174-20.1 | 0.702  |
| RRM2 High / Low                      | 39 / 32 | 1 / 1.64   | 0.117-56.0  | 0.733  |
| Notch3 High / Low                    | 43 / 28 | 1 / 0.0255 | 0.0000483-0.503 | 0.0094 |

PDC, pancreatic ductal carcinoma; N, number; HR, hazard ratio; CI, confidence interval; Ph, head of the pancreas; Pb, body of the pancreas; Pt, tail of the pancreas; GEM, gemcitabine; hENT1, human equilibrative nucleoside transporter 1; dCK, deoxycytidine kinase; RRM1, ribonucleoside reductase 1; RRM2, ribonucleoside reductase 2
Table 3. Multivariate analysis of progression of disease in the GEM population.

| Patient stratification | Multivariate analysis (progression) |
|------------------------|-------------------------------------|
|                        | n        | HR  | 95% CI     | P value    |
| Age (years) < 69 / ≥ 69 | 29 / 27  | 1 / 1.42 | 0.0427-54.1 | 0.836      |
| Sex Female / Male       | 30 / 26  | 1 / 0.396 | 0.0121-5.62 | 0.501      |
| Location Ph / Pb & Pt   | 24 / 32  | 1 / 1.35 | 0.0137-3848 | 0.908      |
| UICC TNM 7th f-Stage III / IV | 18 / 38  | 1 / 0.687 | 0.000491-50.7 | 0.873      |
| Performance status 0 / 1-3 | 49 / 7   | 1 / 54.7 | 0.777-14312 | 0.064      |
| Comorbidities Some / None | 39 / 17  | 1 / 0.281 | 0.00541-3.94 | 0.374      |
| TMs decline < 50% / ≥ 50% | 32 / 24  | 1 / 0.906 | 0.0558-13.0  | 0.939      |
| hENT1 High / Low        | 30 / 26  | 1 / 29.9 | 1.13-8605    | 0.039      |
| dCK High / Low          | 30 / 26  | 1 / 0.199 | 0.00503-2.70 | 0.238      |
| RRM1 High / Low         | 32 / 24  | 1 / 0.180 | 0.00187-3.53 | 0.278      |
| RRM2 High / Low         | 35 / 21  | 1 / 4.63 | 0.155-641    | 0.393      |
| Notch3 High / Low       | 38 / 18  | 1 / 0.233 | 0.000862-8.00 | 0.460      |

GEM, gemcitabine; N, number; HR, hazard ratio; CI, confidence interval; Ph, head of the pancreas; Pb, body of the pancreas; Pt, tail of the pancreas; TMs, tumour markers; hENT1, human equilibrative nucleoside transporter 1; dCK, deoxycytidine kinase; RRM1, ribonucleoside reductase 1; RRM2, ribonucleoside reductase 2.
FIGURE LEGENDS

Figure 1.
Flow diagram of the study participants.

Figure 2.
Kaplan-Meier curves of survival in the gemcitabine (GEM)-treated population according to each mRNA expression level.
Each mRNA expression level was assigned to high or low using the median as a threshold.

Figure 3.
Kaplan-Meier curves of progression-free survival in the GEM-treated population according to each mRNA expression level. Each mRNA expression level was assigned to high or low using the median as a threshold.
Figure 1.

185 patients assessed for eligibility

114 Excluded
- Non adenocarcinoma tumor (n = 75)
- Preoperatory evidence of resectable disease (n = 39)

71 patients included

71 assessable patients with evidence of unresectable PDC

Gemcitabine-based treatment (n = 56)

GEM population (n = 56)

Other drug-based treatment (n = 6)

Non-GEM population (n = 15)

No treatment (n = 9)
Figure 2.
Figure 3.